GGHC
SAGE

Gilder Gagnon Howe & Co’s Sage Therapeutics SAGE Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-324,344
Closed -$9.77M – 282
2016
Q2 		$9.77M Sell
324,344
-26,761
-8% -$892K 0.19% 87
2016
Q1 		$11.3M Sell
351,105
-160,975
-31% -$5.67M 0.22% 80
2015
Q4 		$29.9M Sell
512,080
-304,459
-37% -$15.1M 0.48% 54
2015
Q3 		$34.6M Sell
816,539
-112,758
-12% -$6.95M 0.55% 50
2015
Q2 		$67.8M Buy
+929,297
New +$59.7M 0.89% 35

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gilder Gagnon Howe & Co's SAGE Position: Q3 2016 in Review

Gilder Gagnon Howe & Co sold out of Sage Therapeutics (SAGE) in Q3 2016, closing a stake of 324,344 shares — an estimated $9.77M sold.

Gilder Gagnon Howe & Co first reported a position in SAGE in Q2 2015 and held it in 5 quarters. The position peaked at $67.8M in Q2 2015. 152 funds tracked by Wall St. Rank hold SAGE as of Q3 2016.

  • Gilder Gagnon Howe & Co reported no remaining Sage Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 324,344 Sage Therapeutics shares in Q3 2016, an estimated $9.77M.
  • Gilder Gagnon Howe & Co first reported a position in Sage Therapeutics in Q2 2015 and held it in 5 quarters.
  • Gilder Gagnon Howe & Co's Sage Therapeutics position peaked at $67.8M in Q2 2015.
  • 152 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2016.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2016, filed 1 Nov 2016.